Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
9.06 HKD | -4.53% | -3.40% | -54.28% |
Jun. 13 | Genscript Biotech CEOs to Receive Shares Under Restricted Share Scheme | MT |
Jun. 03 | Hong Kong Stocks Rebound Following More than Expected Growth in China’s Manufacturing Sector | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company sustains low margins.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-54.28% | 2.55B | B | ||
+46.03% | 56.61B | B- | ||
-7.53% | 39.62B | B | ||
+36.02% | 39.25B | A | ||
-9.38% | 28.28B | C | ||
+12.31% | 26.44B | B- | ||
-16.38% | 20.12B | B | ||
+30.79% | 12.51B | B+ | ||
+28.57% | 12.48B | C+ | ||
-0.36% | 12.2B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 1548 Stock
- Ratings Genscript Biotech Corporation